Nasdaq

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a ...
Seeking Alpha

GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients

STAMFORD, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, applauds the decisions by the states of ...
ksn.com

GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in ...

STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the ...
WRIC

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

MENLO PARK, Calif. and STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a ...
WWLP-22News

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms

MENLO PARK, Calif. and STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a ...
Nasdaq

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

New whole genome sequencing test delivers fast, comprehensive insights when fetal anomalies are identified, reinforcing GeneDx’s commitment to enabling precise, fast, and actionable rare disease ...
Morningstar

GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSS

GeneDx operates a data-driven clinical diagnostics business model focused on rare and ultra-rare disease testing, emphasizing its whole genome sequencing and whole exome sequencing tests as primary ...
WREG

GeneDx CEO wants genetic testing for every newborn

GeneDx has a big market in mind for its genetic testing: every newborn baby. The 24-year-old-company wants to make the testing common at birth. The goal: Identify potential diseases or conditions so ...
News Medical

NIH funds multi-state pilot for genome sequencing in newborn screening

Mass General Brigham and Ariadne Labs, alongside Boston Children's Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, ...
Business Wire

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced ultraRapid Whole Genome Sequencing, offering ...
Seeking Alpha

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn., Aug. 7, 2023 /PRNewswire/ -- PacBio (Nasdaq: PACB), a ...